DS 4824
Latest Information Update: 27 Dec 2000
Price :
$50 *
At a glance
- Originator Santen Pharmaceutical
- Developer Daiichi Pharmaceutical; Santen Pharmaceutical
- Class Antiarrhythmics
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 27 Dec 2000 Discontinued-II for Arrhythmias in Japan (PO)
- 16 Nov 2000 No-Development-Reported for Arrhythmias in Japan (PO)
- 23 Jun 1995 Phase-II clinical trials for Arrhythmias in Japan (PO)